Knopp Neurosciences Inc.
Knopp Neurosciences Inc. is a drug discovery and development company focused on delivering breakthrough treatments in neurological disorders. Knopp’s lead compound, KNS-760704, is currently in clinical development for amyotrophic lateral sclerosis, often called Lou Gehrig’s disease, with additional indications under investigation. Led by veteran executives and scientists from the pharmaceutical industry, Knopp’s discovery effort is focused on modulating mitochondrial mechanisms of cell death.
www.knoppneurosciences.com